Compare Sana Biotechnology Inc (SANA) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs SYSCO Corporation — how do they compare? Sana Biotechnology Inc trades at $3.24 (market cap $1.03B), while SYSCO Corporation trades at $81.58 (market cap $38.25B). The key difference: SYSCO Corporation is far larger — about 37.1× Sana Biotechnology Inc's market cap, and SYSCO Corporation pays a 2.76% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | SYY | |
|---|---|---|
Market Cap | $1.03B | $38.25B |
Sector | Health | Consumer Staples |
52-Week High | $5.92 | $91.16 |
52-Week Low | $2.68 | $69.30 |
Enterprise Value | $946.04M | $51.43B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Sysco Corporation (SYY) trades at $79.84, down 0.26% with mixed technical signals showing bullish oscillators but bearish moving averages. The company reported solid Q2 2026 earnings beat ($1.53 vs $1.51 expected) and maintains strong revenue growth, reaching $81.37B in 2025. Recent news highlights the company's $500M AI efficiency program and reaffirmed fiscal 2027 guidance, while analysts maintain a 60% buy rating with $88.25 consensus target.
Sysco presents a compelling investment case with attractive valuation (P/S 0.45), strong institutional interest, and AI-driven efficiency initiatives. However, risks include integration challenges from the Jetro Restaurant Depot acquisition, rising debt levels, and margin pressure from inflationary costs. The stock offers 10% upside to analyst targets but requires monitoring of execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
